RE-COVER II - RE-COVER II

Description:

In the RE-COVER trial, dabigatan, an orally active direct thrombin inhibitor, demonstrated similar efficacy and lower bleeding as compared with warfarin in the treatment of patients with symptomatic venous thromboembolism (VTE). However, this trial had low event rates. Accordingly, the current trial sought to extend these findings in another patient population.